@article {2502, title = {Efficacy and Safety of Propofol Drip versus Thiopental with Midazolam in Children Undergoing Magnetic Resonance Imaging Studies}, journal = {Pharmacognosy Journal}, volume = {17}, year = {2025}, month = {June 2025}, pages = {289-292}, type = {Original Article}, chapter = {289}, abstract = {

Introduction: Pediatrics often require sedatives during Magnetic Resonance Imaging (MRI) due to its lengthy, loud, and restricted space. This study aims to compare efficacy and safety of propofol drip and thiopental with midazolam for children undergoing MRI. Methods: This randomised double-blinded cohort study was conducted in patients aged 3-10 years old with ASA status I-II scheduled for outpatient MRI. Exclusion criteria include airway abnormalities, allergic reactions to anesthetic agents, renal, hepatic, and seizure history, or was pre-medicated. Patients were administered propofol (group PF) or midazolam with thiopental (group TH). Data including patient history, physiologic parameters, duration, recovery, discharge time, and adverse events were recorded. Data was statistically analysed using Chi Square and Student T-test. Results: A total of 34 patients were included in this study, 18 in PF and 16 TH. Sedation onset, recovery time, and mean discharge was significantly shorter in PF versus TH (6 vs 10 mins (p \<0.0001); 8 vs 13 mins (p \<0.0001), and 69 vs 89 mins (p \<0.0001)). No significant differences in duration and physiologic parameters between both groups were found. No adverse events occurred in both groups. 6.25\% of patients in group PF and 33.33\% in group TH had inadequate sedation. Conclusion: This study found PF has faster sedation onset and recovery time in comparison to TH for children undergoing MRI with no significant differences in physiologic parameters and adverse events. Further studies conducted on a larger population investigating efficacy and adverse events of alternative sedatives is recommended.

}, keywords = {Children, MRI, Propofol, Thiopental}, doi = {10.5530/pj.2025.17.36}, author = {Erwin Mulyawan and Clarissa Jasmine Aurelia} } @article {797, title = {Reversible Hepatotoxicity of Cassytha filiformis Extract: Experimental Study on Liver Function and Propofol-Induced Sleep in Mice}, journal = {Pharmacognosy Journal}, volume = {11}, year = {2019}, month = {January 2019}, pages = {69-74}, type = {Original Article}, chapter = {69}, abstract = {

Objective: To study the liver toxicity of Cassytha filiformis L. extract and its reversibility in mice. Methods: A total of 108 male mice were used to investigate the hepatotoxicity of Cassytha filiformis extract (CFE) and the reversibility of its toxicity to the liver. Seventy-two mice were treated with CFE orally for 7 consecutive days. A half of these animals were used to study the sleep time on propofol-induced sleep that comprised the sleep onset time (SOT) and duration of sleep (DOS), while another half was used for the quantitation of serum alanine transaminase (ALT) activity. To investigate the reversibility of the liver toxicity, thirty-six mice were treated with daily CFE for 7 days. Activities of ALT and alkaline phosphatase (ALP) were determined and the liver weight ratio was measured on day 0, 1, 3 and 7 after the termination of the CFE treatment. Data of liver toxicity determination were analyzed by two-way ANOVA followed by Duncan{\textquoteright}s multiple range test, while data of the reversibility was analyzed by Pearson{\textquoteright}s correlation. The significance level was taken at 95\% of confidence interval. Results: CFE shortened the SOT and prolonged the DOS significantly compared with control (p\<0.05). The activity of ALT was increased due to the toxicity of CFE. However, the ALT/ALP activities decreased and liver weight ratio increased gradually after the extract treatment was discontinued. The trend of these data was correlated significantly (p\<0.05). Conclusion: Cassytha filiformis L. extract is toxic to the liver but the toxicity is reversible depending on doses.

}, keywords = {Cassytha filiformis, Liver function, Propofol, Reversible toxicity, Sleep time}, doi = {10.5530/pj.2019.1.13}, author = {Yori Yuliandra and Armenia Armenia and Rahmad Arief and Mifta Hul Jannah and Helmi Arifin} }